<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Management of Skin, Mucosa and Joint Involvement of Behçet&apos;s Syndrome: A Systematic Review for Update of the EULAR Recommendations for the Management of Behçet&apos;s Syndrome</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2017-07-28">28 July 2017</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Pietro</forename><surname>Leccese</surname></persName>
							<affiliation key="aff1">
								<orgName type="department">Rheumatology Department of Lucania</orgName>
								<orgName type="institution" key="instit1">Pietro Leccese</orgName>
								<orgName type="institution" key="instit2">Rheumatology Institute of Lucania (IRel)</orgName>
								<orgName type="institution" key="instit3">San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera</orgName>
								<address>
									<settlement>Potenza and Matera</settlement>
									<region>MD</region>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Yesim</forename><surname>Ozguler</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Yesim Ozguler</orgName>
								<orgName type="department" key="dep2">Division of Rheumatology</orgName>
								<orgName type="department" key="dep3">Department of Internal Medicine</orgName>
								<address>
									<region>MD</region>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Cerrahpasa Medical School</orgName>
								<orgName type="institution">Istanbul University</orgName>
								<address>
									<settlement>Istanbul</settlement>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Division of Rheumatology</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
								<orgName type="institution">Sinem Nihal Esatoglu</orgName>
								<address>
									<region>MD</region>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department">Cerrahpasa Medical School</orgName>
								<orgName type="institution">Istanbul University</orgName>
								<address>
									<settlement>Istanbul</settlement>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
							<affiliation key="aff30">
								<orgName type="department" key="dep1">Sebahattin Yurdakul</orgName>
								<orgName type="department" key="dep2">Division of Rheumatology</orgName>
								<orgName type="department" key="dep3">Department of Internal Medicine</orgName>
								<address>
									<region>MD</region>
								</address>
							</affiliation>
							<affiliation key="aff31">
								<orgName type="department">Cerrahpasa Medical School</orgName>
								<orgName type="institution">Istanbul University</orgName>
								<address>
									<settlement>Istanbul</settlement>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
							<affiliation key="aff33">
								<orgName type="department" key="dep1">Division of Rheumatology</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
								<orgName type="department" key="dep3">Cerrahpasa Medical School</orgName>
								<orgName type="institution" key="instit1">Hasan Yazici</orgName>
								<orgName type="institution" key="instit2">Istanbul University</orgName>
								<address>
									<settlement>Istanbul</settlement>
									<region>MD</region>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
							<affiliation key="aff34">
								<orgName type="department" key="dep1">Division of Rheumatology</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
								<orgName type="institution">Gulen Hatemi</orgName>
								<address>
									<region>MD</region>
								</address>
							</affiliation>
							<affiliation key="aff35">
								<orgName type="department">Cerrahpasa Medical School</orgName>
								<orgName type="institution">Istanbul University</orgName>
								<address>
									<settlement>Istanbul</settlement>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>Sinem</roleName><forename type="first">Robin</forename><surname>Christensen</surname></persName>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Robin Christensen</orgName>
								<orgName type="department" key="dep2">Department of Rheumatology</orgName>
								<orgName type="institution" key="instit1">Musculoskeletal Statistics Unit</orgName>
								<orgName type="institution" key="instit2">The Parker Institute, Bispebjerg and Frederiksberg Hospital</orgName>
								<orgName type="institution" key="instit3">Odense University Hospital</orgName>
								<address>
									<settlement>Copenhagen</settlement>
									<region>MD</region>
									<country key="DK">Denmark</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Nihal</forename><surname>Esatoglu</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Dongsik</forename><surname>Bang</surname></persName>
							<affiliation key="aff7">
								<orgName type="department" key="dep1">Dongsik Bang</orgName>
								<orgName type="department" key="dep2">Department of Dermatology</orgName>
								<orgName type="institution">Catholic Kwandong University International St. Mary&apos;s Hospital</orgName>
								<address>
									<settlement>Incheon</settlement>
									<region>MD</region>
									<country key="KR">Korea</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>Aykut</roleName><forename type="first">Bahram</forename><surname>Bodaghi</surname></persName>
							<affiliation key="aff8">
								<orgName type="department">Department of Ophthalmology</orgName>
								<orgName type="institution" key="instit1">Bahram Bodaghi</orgName>
								<orgName type="institution" key="instit2">Pitié-Salpêtrière Hospital</orgName>
								<orgName type="institution" key="instit3">Sorbonne University</orgName>
								<address>
									<settlement>Paris</settlement>
									<region>MD</region>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ferhat</forename><surname>Celik</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Farida</forename><surname>Fortune</surname></persName>
							<affiliation key="aff11">
								<orgName type="department">Centre for Clinical and Diagnostic Oral Sciences, Barts and the London School of Medicine and Dentistry</orgName>
								<orgName type="institution" key="instit1">Farida Fortune</orgName>
								<orgName type="institution" key="instit2">Queen Mary University of London</orgName>
								<orgName type="institution" key="instit3">London Behçet&apos;s Centre</orgName>
								<orgName type="institution" key="instit4">Barts Health London</orgName>
								<address>
									<settlement>London</settlement>
									<region>MD</region>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Julien</forename><surname>Gaudric</surname></persName>
							<affiliation key="aff12">
								<orgName type="department">Department of Vascular Surgery</orgName>
								<orgName type="institution" key="instit1">Julien Gaudric</orgName>
								<orgName type="institution" key="instit2">Pitié-Salpêtrière Hospital</orgName>
								<orgName type="institution" key="instit3">Sorbonne University</orgName>
								<address>
									<settlement>Paris</settlement>
									<region>MD</region>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ahmet</forename><surname>Gül</surname></persName>
							<affiliation key="aff13">
								<orgName type="department" key="dep1">Division of Rheumatology</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
								<orgName type="department" key="dep3">Istanbul Faculty of Medicine</orgName>
								<orgName type="institution" key="instit1">Ahmet Gül</orgName>
								<orgName type="institution" key="instit2">Istanbul University</orgName>
								<address>
									<settlement>Istanbul</settlement>
									<region>MD</region>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ina</forename><surname>Kötter</surname></persName>
							<affiliation key="aff14">
								<orgName type="department">Department of Rheumatology, Immunology and Nephrology</orgName>
								<orgName type="institution" key="instit1">Ina Kötter</orgName>
								<orgName type="institution" key="instit2">Asklepios Clinic Altona</orgName>
								<address>
									<settlement>Hamburg</settlement>
									<region>MD</region>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Alfred</forename><surname>Mahr</surname></persName>
							<affiliation key="aff15">
								<orgName type="department">Department of Internal Medicine</orgName>
								<orgName type="institution" key="instit1">Alfred Mahr</orgName>
								<orgName type="institution" key="instit2">Hospital Saint-Louis</orgName>
								<address>
									<settlement>Paris</settlement>
									<region>MD</region>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Robert</forename><forename type="middle">J</forename><surname>Moots</surname></persName>
							<affiliation key="aff16">
								<orgName type="department">National Behcet&apos;s Syndrome Centre of Excellence</orgName>
								<orgName type="institution" key="instit1">Robert Moots</orgName>
								<orgName type="institution" key="instit2">Aintree University Hospital</orgName>
								<address>
									<settlement>Liverpool</settlement>
									<region>MD</region>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jutta</forename><surname>Richter</surname></persName>
							<affiliation key="aff17">
								<orgName type="institution" key="instit1">Jutta Richter</orgName>
								<orgName type="institution" key="instit2">Institute for Haematopathology Hamburg</orgName>
								<address>
									<settlement>Hamburg</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">David</forename><surname>Saadoun</surname></persName>
							<affiliation key="aff18">
								<orgName type="department">Department of Inflammation-Immunopathology-Biotherapy</orgName>
								<orgName type="institution">David Saadoun</orgName>
								<address>
									<settlement>Paris</settlement>
									<region>MD</region>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff19">
								<orgName type="institution">INSERM---Inflammatoires</orgName>
								<address>
									<settlement>Paris, Paris</settlement>
									<country>France -, France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Carlo</forename><surname>Salvarani</surname></persName>
							<affiliation key="aff20">
								<orgName type="department">Division of Rheumatology</orgName>
								<orgName type="institution" key="instit1">Carlo Salvarani</orgName>
								<orgName type="institution" key="instit2">Azienda USL-IRCCS di Reggio Emilia</orgName>
								<address>
									<region>MD</region>
								</address>
							</affiliation>
							<affiliation key="aff21">
								<orgName type="institution">University of Modena and Reggio Emilia, Modena and Reggio Emilia</orgName>
								<address>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Francesco</forename><surname>Scuderi</surname></persName>
							<affiliation key="aff22">
								<orgName type="institution">Francesco Scuderi, patient research partner</orgName>
								<address>
									<region>Catania</region>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Petros</forename><forename type="middle">P</forename><surname>Sfikakis</surname></persName>
							<affiliation key="aff23">
								<orgName type="department">First Department of Propaedeutic and Internal Medicine &amp; Rheumatology Unit</orgName>
								<orgName type="institution" key="instit1">Petros P. Sfikakis</orgName>
								<orgName type="institution" key="instit2">National Kapodistrian University of Athens Medical School</orgName>
								<address>
									<settlement>Athens</settlement>
									<region>MD</region>
									<country key="GR">Greece</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Aksel</forename><surname>Siva</surname></persName>
							<affiliation key="aff24">
								<orgName type="department" key="dep1">Department of Neurology</orgName>
								<orgName type="department" key="dep2">Cerrahpasa Medical School</orgName>
								<orgName type="institution" key="instit1">Aksel Siva</orgName>
								<orgName type="institution" key="instit2">Istanbul University</orgName>
								<address>
									<settlement>Istanbul</settlement>
									<region>MD</region>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Miles</forename><surname>Stanford</surname></persName>
							<affiliation key="aff25">
								<orgName type="department">Department of Ophthalmology</orgName>
								<orgName type="institution">Miles Stanford</orgName>
								<address>
									<settlement>St</settlement>
									<region>MD</region>
								</address>
							</affiliation>
							<affiliation key="aff26">
								<orgName type="institution">Thomas&apos; Hospital</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">United Kingdom</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ilknur</forename><surname>Tugal-Tutkun</surname></persName>
							<affiliation key="aff27">
								<orgName type="department" key="dep1">Department of Ophthalmology</orgName>
								<orgName type="department" key="dep2">Istanbul Faculty of Medicine</orgName>
								<orgName type="institution">Ilknur Tugal-Tutkun</orgName>
								<address>
									<region>MD</region>
								</address>
							</affiliation>
							<affiliation key="aff28">
								<orgName type="institution">Istanbul University</orgName>
								<address>
									<settlement>Istanbul</settlement>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Richard</forename><surname>West</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Sebahattin</forename><surname>Yurdakul</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Yesim Ozguler</orgName>
								<orgName type="department" key="dep2">Division of Rheumatology</orgName>
								<orgName type="department" key="dep3">Department of Internal Medicine</orgName>
								<address>
									<region>MD</region>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Cerrahpasa Medical School</orgName>
								<orgName type="institution">Istanbul University</orgName>
								<address>
									<settlement>Istanbul</settlement>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Division of Rheumatology</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
								<orgName type="institution">Sinem Nihal Esatoglu</orgName>
								<address>
									<region>MD</region>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department">Cerrahpasa Medical School</orgName>
								<orgName type="institution">Istanbul University</orgName>
								<address>
									<settlement>Istanbul</settlement>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
							<affiliation key="aff30">
								<orgName type="department" key="dep1">Sebahattin Yurdakul</orgName>
								<orgName type="department" key="dep2">Division of Rheumatology</orgName>
								<orgName type="department" key="dep3">Department of Internal Medicine</orgName>
								<address>
									<region>MD</region>
								</address>
							</affiliation>
							<affiliation key="aff31">
								<orgName type="department">Cerrahpasa Medical School</orgName>
								<orgName type="institution">Istanbul University</orgName>
								<address>
									<settlement>Istanbul</settlement>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
							<affiliation key="aff33">
								<orgName type="department" key="dep1">Division of Rheumatology</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
								<orgName type="department" key="dep3">Cerrahpasa Medical School</orgName>
								<orgName type="institution" key="instit1">Hasan Yazici</orgName>
								<orgName type="institution" key="instit2">Istanbul University</orgName>
								<address>
									<settlement>Istanbul</settlement>
									<region>MD</region>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
							<affiliation key="aff34">
								<orgName type="department" key="dep1">Division of Rheumatology</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
								<orgName type="institution">Gulen Hatemi</orgName>
								<address>
									<region>MD</region>
								</address>
							</affiliation>
							<affiliation key="aff35">
								<orgName type="department">Cerrahpasa Medical School</orgName>
								<orgName type="institution">Istanbul University</orgName>
								<address>
									<settlement>Istanbul</settlement>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ignazio</forename><surname>Olivieri</surname></persName>
							<affiliation key="aff32">
								<orgName type="department">Rheumatology Department of Lucania</orgName>
								<orgName type="institution" key="instit1">Ignazio Olivieri</orgName>
								<orgName type="institution" key="instit2">Rheumatology Institute of Lucania (IRel)</orgName>
								<orgName type="institution" key="instit3">San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera</orgName>
								<orgName type="institution" key="instit4">Basilicata Ricerca Biomedica (BRB) Foundation, Potenza and Matera</orgName>
								<address>
									<region>MD</region>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hasan</forename><surname>Yazici</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Yesim Ozguler</orgName>
								<orgName type="department" key="dep2">Division of Rheumatology</orgName>
								<orgName type="department" key="dep3">Department of Internal Medicine</orgName>
								<address>
									<region>MD</region>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Cerrahpasa Medical School</orgName>
								<orgName type="institution">Istanbul University</orgName>
								<address>
									<settlement>Istanbul</settlement>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Division of Rheumatology</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
								<orgName type="institution">Sinem Nihal Esatoglu</orgName>
								<address>
									<region>MD</region>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department">Cerrahpasa Medical School</orgName>
								<orgName type="institution">Istanbul University</orgName>
								<address>
									<settlement>Istanbul</settlement>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
							<affiliation key="aff30">
								<orgName type="department" key="dep1">Sebahattin Yurdakul</orgName>
								<orgName type="department" key="dep2">Division of Rheumatology</orgName>
								<orgName type="department" key="dep3">Department of Internal Medicine</orgName>
								<address>
									<region>MD</region>
								</address>
							</affiliation>
							<affiliation key="aff31">
								<orgName type="department">Cerrahpasa Medical School</orgName>
								<orgName type="institution">Istanbul University</orgName>
								<address>
									<settlement>Istanbul</settlement>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
							<affiliation key="aff33">
								<orgName type="department" key="dep1">Division of Rheumatology</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
								<orgName type="department" key="dep3">Cerrahpasa Medical School</orgName>
								<orgName type="institution" key="instit1">Hasan Yazici</orgName>
								<orgName type="institution" key="instit2">Istanbul University</orgName>
								<address>
									<settlement>Istanbul</settlement>
									<region>MD</region>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
							<affiliation key="aff34">
								<orgName type="department" key="dep1">Division of Rheumatology</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
								<orgName type="institution">Gulen Hatemi</orgName>
								<address>
									<region>MD</region>
								</address>
							</affiliation>
							<affiliation key="aff35">
								<orgName type="department">Cerrahpasa Medical School</orgName>
								<orgName type="institution">Istanbul University</orgName>
								<address>
									<settlement>Istanbul</settlement>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Gulen</forename><surname>Hatemi</surname></persName>
							<email>gulenhatemi@yahoo.com</email>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Yesim Ozguler</orgName>
								<orgName type="department" key="dep2">Division of Rheumatology</orgName>
								<orgName type="department" key="dep3">Department of Internal Medicine</orgName>
								<address>
									<region>MD</region>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Cerrahpasa Medical School</orgName>
								<orgName type="institution">Istanbul University</orgName>
								<address>
									<settlement>Istanbul</settlement>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Division of Rheumatology</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
								<orgName type="institution">Sinem Nihal Esatoglu</orgName>
								<address>
									<region>MD</region>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department">Cerrahpasa Medical School</orgName>
								<orgName type="institution">Istanbul University</orgName>
								<address>
									<settlement>Istanbul</settlement>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
							<affiliation key="aff30">
								<orgName type="department" key="dep1">Sebahattin Yurdakul</orgName>
								<orgName type="department" key="dep2">Division of Rheumatology</orgName>
								<orgName type="department" key="dep3">Department of Internal Medicine</orgName>
								<address>
									<region>MD</region>
								</address>
							</affiliation>
							<affiliation key="aff31">
								<orgName type="department">Cerrahpasa Medical School</orgName>
								<orgName type="institution">Istanbul University</orgName>
								<address>
									<settlement>Istanbul</settlement>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
							<affiliation key="aff33">
								<orgName type="department" key="dep1">Division of Rheumatology</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
								<orgName type="department" key="dep3">Cerrahpasa Medical School</orgName>
								<orgName type="institution" key="instit1">Hasan Yazici</orgName>
								<orgName type="institution" key="instit2">Istanbul University</orgName>
								<address>
									<settlement>Istanbul</settlement>
									<region>MD</region>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
							<affiliation key="aff34">
								<orgName type="department" key="dep1">Division of Rheumatology</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
								<orgName type="institution">Gulen Hatemi</orgName>
								<address>
									<region>MD</region>
								</address>
							</affiliation>
							<affiliation key="aff35">
								<orgName type="department">Cerrahpasa Medical School</orgName>
								<orgName type="institution">Istanbul University</orgName>
								<address>
									<settlement>Istanbul</settlement>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sinem</forename><surname>Nihal Esatoglu</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Yesim Ozguler</orgName>
								<orgName type="department" key="dep2">Division of Rheumatology</orgName>
								<orgName type="department" key="dep3">Department of Internal Medicine</orgName>
								<address>
									<region>MD</region>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Cerrahpasa Medical School</orgName>
								<orgName type="institution">Istanbul University</orgName>
								<address>
									<settlement>Istanbul</settlement>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Division of Rheumatology</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
								<orgName type="institution">Sinem Nihal Esatoglu</orgName>
								<address>
									<region>MD</region>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department">Cerrahpasa Medical School</orgName>
								<orgName type="institution">Istanbul University</orgName>
								<address>
									<settlement>Istanbul</settlement>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
							<affiliation key="aff30">
								<orgName type="department" key="dep1">Sebahattin Yurdakul</orgName>
								<orgName type="department" key="dep2">Division of Rheumatology</orgName>
								<orgName type="department" key="dep3">Department of Internal Medicine</orgName>
								<address>
									<region>MD</region>
								</address>
							</affiliation>
							<affiliation key="aff31">
								<orgName type="department">Cerrahpasa Medical School</orgName>
								<orgName type="institution">Istanbul University</orgName>
								<address>
									<settlement>Istanbul</settlement>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
							<affiliation key="aff33">
								<orgName type="department" key="dep1">Division of Rheumatology</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
								<orgName type="department" key="dep3">Cerrahpasa Medical School</orgName>
								<orgName type="institution" key="instit1">Hasan Yazici</orgName>
								<orgName type="institution" key="instit2">Istanbul University</orgName>
								<address>
									<settlement>Istanbul</settlement>
									<region>MD</region>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
							<affiliation key="aff34">
								<orgName type="department" key="dep1">Division of Rheumatology</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
								<orgName type="institution">Gulen Hatemi</orgName>
								<address>
									<region>MD</region>
								</address>
							</affiliation>
							<affiliation key="aff35">
								<orgName type="department">Cerrahpasa Medical School</orgName>
								<orgName type="institution">Istanbul University</orgName>
								<address>
									<settlement>Istanbul</settlement>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Aykut</forename><surname>Ferhat Celik</surname></persName>
							<affiliation key="aff9">
								<orgName type="department" key="dep1">Division of Gastroenterology</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
								<orgName type="institution">Aykut Ferhat Celik</orgName>
								<address>
									<region>MD</region>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="department">Cerrahpasa Medical School</orgName>
								<orgName type="institution">Istanbul University</orgName>
								<address>
									<settlement>Istanbul</settlement>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department">Management of Skin</orgName>
								<address>
									<settlement>Mucosa</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff29">
								<orgName type="institution">Behcets International</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff36">
								<orgName type="department" key="dep1">Division of Rheumatology</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
								<orgName type="department" key="dep3">Cerrahpasa Medical School</orgName>
								<orgName type="institution">Istanbul University</orgName>
								<address>
									<postCode>34098</postCode>
									<settlement>Istanbul</settlement>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Management of Skin, Mucosa and Joint Involvement of Behçet&apos;s Syndrome: A Systematic Review for Update of the EULAR Recommendations for the Management of Behçet&apos;s Syndrome</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2017-07-28">28 July 2017</date>
						</imprint>
					</monogr>
					<idno type="MD5">69932B85D6325B382FB7FA168D1CDA4B</idno>
					<idno type="DOI">10.1016/j.semarthrit.2018.05.008</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:16+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>This is a PDF file of an unedited manuscript that has been accepted for publication.</s><s>As a service to our customers we are providing this early version of the manuscript.</s><s>The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form.</s><s>Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Abstract</head><p><s>Objectives: The aim of this systematic review was to inform the update of European League h (E L ) h B hç ' syndrome (BS), on the evidence for the treatment of skin, mucosa and joint involvement of BS.</s></p><p><s>Methods: A systematic literature search, data extraction, statistical analyses and assessment of the quality of evidence were performed according to a pre-specified protocol using the PRISMA guidelines.</s><s>Studies that assessed the efficacy of an intervention in comparison to an active comparator or placebo for oral ulcers, genital ulcers, papulopustular lesions, nodular lesions or arthritis were included.</s><s>Where possible, risk ratios were calculated for binary outcomes and mean difference for continuous outcomes.</s></p><p><s>Results: Among the 3,927 references that were screened, 37 were included in the analyses.</s></p><p><s>Twenty-seven of these assessed mucocutaneous and 17 assessed joint involvement.</s><s>Twentyone of these studies were randomised controlled trials (RCTs).</s><s>RCTs with colchicine, azathioprine, interferon-alpha, thalidomide, etanercept and apremilast showed beneficial results with some differences according to lesion type and gender.</s><s>These agents were generally well tolerated with few adverse events causing withdrawal from the study.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions:</head><p><s>RCTs comprised more than a half (21/37, 57%) of the sources included in the evidence synthesis related to skin, mucosa and joint involvement applicable for the EULAR Recommendations for the management of BS.</s><s>Differences in the outcome measures that were used across the included studies often made it difficult to combine and compare the results.</s></p><p><s>Keywords: B hç ' , treatment, anti-TNF, systematic review</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>1.Introduction</head><p><s>B hç ' (BS) is a primary systemic vasculitis that can involve arteries of all sizes as well as veins <ref type="bibr" target="#b0">[1]</ref>.</s><s>The clinical hallmarks of BS that occur in almost all of the patients are mucocutaneous manifestations which include oral apthous ulcers, genital ulcers, papulopustular lesions and erythema nodosum.</s><s>Other manifestations of BS include arthritis, eye, central nervous system, gastrointestinal and vascular involvement that can cause significant morbidity and mortality <ref type="bibr" target="#b1">[2]</ref>.</s><s>Mucocutaneous and articular manifestations typically have a relapsing and remitting, self-limited course.</s><s>Although these are not life threatening manifestations they can have an important (negative) impact on quality of life <ref type="bibr" target="#b2">[3]</ref>.</s><s>The treatment goals are reducing the inflammatory process, improving quality of life and preventing relapses.</s></p><p><s>Th 2 8 E L h B hç ' disease, now termed BS for reasons explained in the Recommendations manuscript, are updated under the auspices of the EULAR Standing Committe for Clinical Affairs (ESCCA) <ref type="bibr" target="#b3">[4]</ref>.</s><s>The aim of this systematic review was to provide the evidence synthesis needed to inform the task force for updating the Recommendations, about the evidence for the treatment of skin, mucosa and joint involvement of BS.</s><s>Major organ involvement is addressed in a separate systematic review.</s><s>The scope of this work was to expand knowledge on agents already present in the previous review and on newer biological and non-biological agents available so far.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>2.Methods</head><p><s>The systematic literature search, data extraction and statistical analyses were performed according to a pre-specified protocol according to the principles stated in the PRISMA guidelines <ref type="bibr" target="#b4">[5]</ref>.</s><s>The protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO) with number CRD42015027033.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1">Search strategy</head><p><s>Specific research questions were identified through a Delphi process among the task force members and reformulated according to the PICO format (Patients, Interventions, Comparison and Outcomes) <ref type="bibr" target="#b5">[6]</ref>.</s><s>The research questions, keywords, databases that were searched, details of study selection and data extraction are provided in the online supplement.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2">Data analysis</head><p><s>We calculated the mean difference (MD) with 95% confidence interval (CI) for continuous outcomes <ref type="bibr" target="#b6">[7]</ref> and the risk ratio (RR) with 95% CI for dichotomous outcomes <ref type="bibr" target="#b7">[8]</ref>.</s><s>When the MD equals zero, this means that there is no difference between the treatment groups.</s><s>When the mean difference is greater than 0 and the 95% CI does not contain 0, this indicates that the " is better than the ".</s><s>When the risk ratio equals 1, this means that there is no difference in the probability of an outcome occurring across the treatment groups.</s></p><p><s>When RR is greater than 1 and the 95% CI does not include the null value (RR=1), this indicates that h " h h ".</s><s>The assessment of risk of bias w h h ' k B T .</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>3.Results</head><p><s>The search identified 3,927 potentially eligible articles; 395 were selected for full-text review and finally 21 randomised controlled trials (RCTs) and 16 observational studies were included.</s><s>Figure describes the study selection process and Table <ref type="table" target="#tab_6">1</ref> describes the characteristics of the eligible RCTs.</s><s>The quality assessment and risk of bias assessment of these RCTs are provided in the online supplement (Figure <ref type="figure">1</ref> and 2).</s><s>The results of the systematic review are sorted by type of clinical manifestation.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1.">Oral ulcers</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1.1.">Systemic treatment</head><p><s>Among the 17 RCTs that reported on outcomes assessing the response of oral ulcers to different drugs, 12 evaluated systemic treatment modalities (Table <ref type="table" target="#tab_2">2</ref>).</s><s>Three RCTs assessed the efficacy of colchicine in managing oral ulcers <ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref>.</s><s>The first study was a double-blind, placebo controlled study involving 28 patients.</s><s>Colchicine 1.5 mg/day used for 6 months was ineffective for oral ulcers (RR 0.75, 95%CI 0.48 to 1.17</s><s>There was one double-blind, placebo-controlled study with azathioprine (2.5 mg/kg/day) that involved only men with and without eye disease <ref type="bibr" target="#b11">[12]</ref>.</s><s>After 24 months the number of patients with active oral ulcers was lower in the azathioprine group (RR 0.34, 95%CI 0.12 to 0.99).</s></p><p><s>There were no serious adverse events.</s></p><p><s>One RCT evaluated the efficacy of interferon-alpha-2a (6x10 6 IU 3 times per week) compared to placebo for the treatment of mucocutaneous manifestations <ref type="bibr" target="#b12">[13]</ref>.</s><s>Complete remission was obtained in 2 of 23 patients in the interferon-alpha-2a group and in none of the 21 patients in the placebo group (RR 4.58, 95%CI 0.23 to 90.3).</s><s>No patients were withdrawn due to toxicity.</s></p><p><s>The only RCT with a tumor necrosis factor alpha inhibitor (TNFi) was the 4 week, doubleblind, placebo-controlled trial with etanercept (25 mg twice a week) that involved 40 men without major organ involvement <ref type="bibr" target="#b13">[14]</ref>.</s><s>Complete remission of oral ulcers was achieved in 9 of 20 patients (45%) in the etanercept arm and in 1 of 20 patients (5%) in the placebo arm (RR 9, 95%CI 1.25 to 64.6).</s><s>One patient in the etanercept arm discontinued the study because of diarrhoea.</s></p><p><s>In a 24 week, double-blind, placebo-controlled trial, 96 men with BS were randomised to receive thalidomide (100 mg/day or 300 mg/day) or placebo <ref type="bibr" target="#b14">[15]</ref>.</s><s>Remission of oral and genital ulcers during 24 weeks was achieved with the dose of 100 mg/day at and between visits (RR 5, 95%CI: 0.25 to 100) and at visits only (RR 21, 95%CI 1.28 to 343).</s><s>Four patients were withdrawn due to toxicity (3 for severe sedation and 1 for polyneuropathy).</s></p><p><s>Rebamipide (300 mg/day) showed a trend for being more effective compared to placebo for improving oral ulcers at 6 months (RR 1.85, 95%CI 0.81 to 4.21) in a RCT <ref type="bibr">[16]</ref>.</s><s>No serious adverse events were reported.</s></p><p><s>In a 3-month, double-blind, placebo-controlled, cross-over trial dapsone (100 mg/day) provided a significant decrease in the number (MD -2.70, 95%CI -3.75 to -1.65 ulcers) and frequency of oral ulcers (MD -1.0, 95%CI -1.72 to -0.27 ulcers per month) <ref type="bibr">[17]</ref>.</s><s>No patients were withdrawn due to serious adverse events.</s></p><p><s>In the only RCT with a corticosteroid (40 mg methylprednisolone acetate i.m. every 3 weeks) no beneficial effect on reducing the number of oral ulcers was obtained (MD 0, 95%CI -0.</s><s>Complete remission rate of oral ulcers was also higher with apremilast (RR 2.48, 95%CI 1.59 to 3.88).</s><s>Two serious adverse events, 1 diplegia and 1 anal fissure and hemorrhoids were observed in patients receiving apremilast.</s></p><p><s>Benzathine penicillin showed a trend for reducing the frequency (MD -0.29, 95%CI -0.86 to 0.26 ulcer), and duration (MD -0.20, 95%CI -1.29 to 0.89 days) of oral ulcers [20].</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1.2.">Topical treatment</head><p><s>There were 5 RCTs evaluating topical treatment.</s><s>Topical sucralfate applied 4 times a day for 12 weeks was not effective in reducing the frequency of oral ulcers (MD -0.80, 95%CI -2.12 to 0.52 ulcers) <ref type="bibr">[21]</ref>.</s><s>Topical interferon-alpha-2c hydrogel (1x10 6 U/g) applied 3 times a day for 24 weeks was also not effective in the treatment of oral ulcers <ref type="bibr" target="#b15">[22]</ref>.</s><s>In the other RCT evaluating topical interferon-alpha at a dose of 1000 IU/day and 2000 IU/day for oral ulcers, neither of the two compounds were effective in reducing the total ulcer burden <ref type="bibr" target="#b16">[23]</ref>.</s></p><p><s>Phenytoin syrup was more effective than triamcinolone acetonide ointment for oral ulcers <ref type="bibr" target="#b17">[24]</ref>.</s><s>The last RCT with topical cyclosporine-A failed to show an effect on the number, size and healing time of oral ulcers <ref type="bibr" target="#b18">[25]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1.3.">Observational studies</head><p><s>Observational studies with mycophenolate mofetil, azithromycin and anakinra showed response in some of the patients whereas tocilizumab caused a paradoxic increase in mucocutaneous lesion as summarized in the online supplement <ref type="bibr" target="#b19">[26]</ref><ref type="bibr" target="#b20">[27]</ref><ref type="bibr" target="#b21">[28]</ref><ref type="bibr" target="#b22">[29]</ref><ref type="bibr">[30]</ref><ref type="bibr" target="#b24">[31]</ref><ref type="bibr" target="#b25">[32]</ref><ref type="bibr" target="#b26">[33]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2.">Genital ulcers</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2.1.">Systemic treatment</head><p><s>Among the 3 RCTs with colchicine (Table <ref type="table" target="#tab_3">3</ref>), the drug was effective in reducing the number of genital ulcers only in one study and only among women (MD -2.50, 95%CI -4.24 to -0.75 ulcers) <ref type="bibr" target="#b9">[10]</ref>.</s><s>Azathioprine was effective in reducing the frequency of genital ulcers after 2 years of treatment (RR 0.08, 95%CI 0.01 to 0.63 ulcers) <ref type="bibr" target="#b11">[12]</ref>.</s><s>Benzathine penicillin was also effective in reducing the frequency (MD -0.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2.2.">Topical treatment</head><p><s>Sucralfate suspension applied topically 4 times a day for 3 months did not significantly reduce the healing time (MD -3.92, 95%CI -9.02 to 1.18 days), or frequency of genital ulcers (MD 0.02, 95%CI -0.63 to 0.67 ulcers) <ref type="bibr">[21]</ref>.</s><s>In one RCT pimecrolimus cream was effective in shortening the healing time of genital ulcers (MD -10, 95%CI -14.68 to -5.32 days) <ref type="bibr" target="#b27">[34]</ref>.</s></p><p><s>However in the other RCT, pimecrolimus was beneficial for shortening the duration of pain but not the healing time of genital ulcers <ref type="bibr" target="#b28">[35]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3.">Skin lesions</head><p><s>There was a trend for decrease in the number of nodular lesions only among women (MD -4.60, 95%CI -10 to 1.20 lesions) in one of the colchicine trials <ref type="bibr" target="#b9">[10]</ref> and there was a significant decrease with colchicine compared to placebo among the whole group (MD -0.35 95%CI -0.57 to -0.12 lesions) in the other colchicine trial (Table <ref type="table" target="#tab_4">4</ref>) <ref type="bibr" target="#b10">[11]</ref>.</s><s>There were significantly more patients with remission in erythema nodosum at week 4 in the etanercept group None of the systemic treatment modalities were proven to be effective for papulopustular lesions in the RCTs with colchicine <ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref>, azathioprine <ref type="bibr" target="#b11">[12]</ref>, etanercept <ref type="bibr" target="#b13">[14]</ref> or depot corticosteroid [18].</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.4.">Arthritis</head><p><s>Nine RCTs reported on the efficacy of 7 different agents in managing arthritis (Table <ref type="table" target="#tab_5">5</ref>).</s><s>The first study with colchicine reported no difference from placebo, but this may have been due to the small sample size (5 patients in each arm).</s><s>There were significantly more patients with complete response of arthritis in one of the colchicine trials at month 24 among both men (RR 1.53, 95%CI 1.16 to 2.02) and women (RR 1.47, 95%CI 1.11 to 1.97) <ref type="bibr" target="#b9">[10]</ref>.</s><s>There was a trend for improvement in the mean IBDDAM joint score at week 16 in the third colchicine trial (MD -0.21, 95%CI -0.49 to 0.07) .</s><s>The RCT with azathioprine also showed a trend for preventing new arthritis attacks in the azathioprine group (RR 0.13, 95%CI 0.02 to 1.00) <ref type="bibr" target="#b11">[12]</ref>.</s></p><p><s>Benzathine penicillin showed efficacy in reducing the mean number of arthritis attacks during 24 months (MD -0.60, 95%CI -0.92 to -0.28 attacks), and in preventing new attacks among patients with no prior history of arthritis (RR 0.16, 95%CI 0.02 to 1.17) <ref type="bibr" target="#b29">[36]</ref>.</s><s>Etanercept did not provide a statistically significant difference from placebo in the number of patients with complete response of arthritis (RR 1.06, 95%CI 0.88 to 1.26) and the number of swollen joints (MD -0.10, 95%CI -0.43 to 0.23 joints) <ref type="bibr" target="#b13">[14]</ref>.</s><s>However, in this 4-week trial there was a high response rate in the placebo group, reflecting the relapsing and remitting nature of arthritis in BS.</s><s>Intramuscular methylprednisolone acetate 40 mg every 3 weeks did not decrease the mean number of arthritis attacks during 27 weeks (MD: 0, 95%CI -0.15 to 0.15 attacks) <ref type="bibr">[18]</ref>.</s><s>Thalidomide 100 mg/day showed no improvement in the number of patients with arthritis (RR 1.25, 95%CI 0.37 to 4.23) and in the number of arthritis episodes during 24 weeks (RR 0.64, 95%CI 0.28 to 1.43) <ref type="bibr" target="#b14">[15]</ref>.</s><s>Thalidomide 300 mg/day was also ineffective for both outcomes (RR 0.52, 95%CI 0.10 to 2.62 and RR 0.38, 95%CI 0.13 to 1.05, respectively) <ref type="bibr" target="#b14">[15]</ref>.</s><s>In the only RCT with a non-steroidal anti-inflammatory drug, azapropazone 900 mg/day was not effective in reducing the number of patients with persistence of arthritis (RR 1.29, 95%CI 0.74 to 2.25), number of patients with new arthritis attacks (RR 0.69, 95%CI 0.28 to 1.69), and mean duration of arthritis attacks (MD: 2.90, 95%CI -1.11 to 6.91 days) <ref type="bibr" target="#b30">[37]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.4.1.">Observational studies</head><p><s>Interferon-alpha was beneficial for the treatment of arthritis in 4 observational studies.</s><s>Three of these reported complete response in all of 11, 24 and 8 patients respectively and one showed a significant decrease in the mean duration and the frequency of arthritis in 9 patients as explained in more detail in the online supplement <ref type="bibr" target="#b31">[38]</ref><ref type="bibr" target="#b32">[39]</ref><ref type="bibr" target="#b33">[40]</ref><ref type="bibr" target="#b34">[41]</ref> .</s><s>Four studies reported favourable results with infliximab for joint involvement.</s><s>Among them, the indication for infliximab was uveitis in 2, gastrointestinal involvement in 1 and arthritis in 1 study <ref type="bibr" target="#b35">[42]</ref><ref type="bibr" target="#b36">[43]</ref><ref type="bibr" target="#b37">[44]</ref><ref type="bibr" target="#b38">[45]</ref>.</s></p><p><s>Infliximab provided complete response in 30 of 32 patients (94%).</s><s>Improvement in arthritis was observed in 6 of 10 patients treated with adalimumab <ref type="bibr" target="#b38">[45]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">Discussion</head><p><s>Several immunomodulatory and immunosuppressive agents have shown beneficial results in decreasing the frequency of mucocutaneous lesions and arthritis episodes.</s><s>Around one half of patients with BS have one or more type of major organ involvement such as eye, vascular, nervous system and gastrointestinal involvement in addition to skin, mucosa and joint lesions.</s></p><p><s>In such patients the systemic immunosuppressives that are used for major organ involvement are usually enough to prevent mucocutaneous and joint lesions and topical agents may be used for shortening the duration and decreasing the pain of occasional lesions.</s></p><p><s>In contrast to major organ involvement of BS, skin, mucosa and joint lesions do not cause damage and are not organ or life threatening apart from rare instances of major oral/pharyngeal ulcerations.</s><s>However they cause pain and can be disabling due to difficulty in performing daily activities such as eating, talking, and moving.</s><s>Thus, when treating patients with only skin, mucosa and joint involvement, the major concern is to improve the quality of life without causing harm.</s><s>Few serious adverse events were reported in the RCTs included in this review.</s><s>However some of these studies had a short duration and the frequency of adverse events may increase with long term use.</s><s>Moreover some of the therapeutic modalities may cause an impairment in quality of life without causing serious adverse events.</s><s>A good example to this is interferon-alpha that causes flu-like symptoms in the majority of patients and depression in about one fourth <ref type="bibr" target="#b39">[46]</ref>.</s><s>Trials that assess the overall effect of treatment modalities on patient important outcomes are necessary to help making treatment decisions for mucocutaneous and joint involvement of BS.</s></p><p><s>The main limitation of this systematic review was the heterogeneity in the outcome measures that were used across the included studies.</s><s>This made it impossible to bring together the results of trials in a meta-analysis, which would especially be desirable for evaluating the efficacy of colchicine for oral ulcers where conflicting results were reported in RCTs.</s></p><p><s>Moreover, no head-to-head trials directly comparing the efficacy of treatment modalities were available.</s><s>The lack of standard outcome measures made it very difficult to make even an indirect comparison of the efficacy of different agents.</s></p><p><s>In conclusion, this systematic review formed the basis for the recommendations related to</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc><div><p><s>).</s><s>The second study was a 2-year, double-blind, placebo controlled study conducted among a larger cohort of BS patients and the results of treatment with colchicine (1-2 mg/day, adjusted according to body weight) were separately evaluated for men and women.</s><s>Colchicine did not statistically significantly improve the number of oral ulcers in women (MD -5.73, 95%CI -12.6 to 1.16 ulcers) or men (MD 0.80, 95%CI -7.83 to 9.47 ulcers).</s><s>The third study was a randomised, placebo controlled, double-blind, crossover trial conducted among 169 patients.</s><s>The primary endpoint was disease act h B hç ' (IBDDAM) score.</s><s>There was a trend for improvement in mean IBDDAM score for oral ulcers in the colchicine group compared to placebo (MD -0.55, 95%CI -0.99 to 0.10).</s><s>Colchicine was generally well tolerated.</s><s>Only one patient had to stop treatment due to nausea and vomiting in one of the RCTs.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc><div><p><s>compared to placebo (RR 3.40, 95%CI 1.56 to 7.43)<ref type="bibr" target="#b13">[14]</ref>.</s><s>Methylprednisolone acetate (40 mg every 3 weeks) decreased the number of nodular lesions compared to placebo (MD -0.20, 95%CI: -0.37 to -0.02 lesions)[18].</s><s>The number of nodular lesions increased during the first 2 months of thalidomide use compared to placebo<ref type="bibr" target="#b14">[15]</ref>.</s><s>The authors considered that these nodular lesions may have been superficial thrombophlebitis lesions, which are difficult to differentiate from erythema nodosum clinically.</s><s>Benzathine penicillin was effective in reducing the frequency (MD -0.0, 95%CI -0.49 to -0.30 lesions), duration (MD -1.00, 95%CI -1.55 to -0.44 days) and severity (MD -0.10, 95%CI -0.18 to -0.01) but not the number (MD -0.10, 95%CI -0.51 to 0.31 lesions) of nodular lesions[20].</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head></head><label></label><figDesc><div><p><s>vs 11/32 LOW</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head></head><label></label><figDesc><div><p><s>[14]95%CI -0.53 to -0.07 ulcers)[20].There was a trend for inducing remission of genital ulcers with etanercept compared to placebo (RR 0.82, 95%CI 0.59 to 1.16)[14].In one RCT dapsone was effective in reducing the number of genital ulcers (MD -0.50, 95%CI -1.02 to -0.03 ulcers)[17].</s><s>No improvement in genital ulcers</s></p></div></figDesc><table /><note><p><s>was observed with methylprednisolone acetate 40 mg every 3 weeks for 27 weeks [18].</s><s>In the apremilast trial all of the 10 patients with genital ulcers in the apremilast group were free of genital ulcers at week 12 compared to 3 of 6 patients in the placebo group (RR 2, 95%CI 0.90 to 4.45) [19].</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Efficacy of interventions for oral ulcers</s></p></div></figDesc><table><row><cell>double-</cell></row></table><note><p><s>skin, mucosa and joint involvement in the updated EULAR Recommendations for the management of BS.</s><s>Randomised controlled trials comprised slightly more than half (21/37, 57%) of the sources informing these Recommendations.</s><s>Matsuda T, Ohno S, Hirohata S, et al.</s><s>Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behcet's disease: a randomised,</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 3 .</head><label>3</label><figDesc><div><p><s>Efficacy of interventions for genital ulcers</s></p></div></figDesc><table /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 4 .</head><label>4</label><figDesc><div><p><s>Efficacy of interventions for skin lesions</s></p></div></figDesc><table /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 5 .</head><label>5</label><figDesc><div><p><s>Efficacy of interventions for arthritis</s></p></div></figDesc><table><row><cell>Figure. Flowchart of study selection</cell></row><row><cell>*Some trials assessed more than one type of involvement.</cell></row><row><cell>Obs: observational study</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Characteristics of RCTs for mucocutaneous and joint involvement of Behçet's syndrome</s></p></div></figDesc><table><row><cell>Author,</cell><cell>Drug</cell><cell>Dose</cell><cell>Trial</cell><cell>Sex</cell><cell>Age</cell><cell></cell><cell>Disease</cell><cell></cell><cell>Main</cell></row><row><cell>year</cell><cell></cell><cell></cell><cell>Duration</cell><cell>M/W</cell><cell>(mean</cell><cell></cell><cell>duration,</cell><cell>Number</cell><cell>outcomes</cell></row><row><cell></cell><cell></cell><cell></cell><cell>(weeks)</cell><cell></cell><cell>±SD</cell><cell></cell><cell>(mean</cell><cell>of</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>years)</cell><cell></cell><cell>±SD</cell><cell>Patients</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>years)</cell><cell></cell></row><row><cell>Aktulga,</cell><cell>Colchicine</cell><cell>1 mg/day</cell><cell>36</cell><cell>9/5</cell><cell cols="2">34.2 ± 7.2</cell><cell>NA</cell><cell>14</cell><cell>Improvement</cell></row><row><cell>1980 [9]</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>in</cell><cell>each</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>mucocutaneous</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>lesion, eye and</cell></row><row><cell></cell><cell>Placebo</cell><cell></cell><cell></cell><cell>13/1</cell><cell cols="2">33 ± 12.8</cell><cell></cell><cell>14</cell><cell>joint</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>involvement</cell></row><row><cell>Yurdakul,</cell><cell>Colchicine</cell><cell>1-2 mg/day</cell><cell>104</cell><cell>30/0</cell><cell>Men</cell><cell></cell><cell>Men</cell><cell>30</cell></row><row><cell>2001[10]</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>27 ± 5.5</cell><cell></cell><cell>8.2 ± 8.4</cell><cell></cell></row><row><cell></cell><cell>Placebo</cell><cell></cell><cell></cell><cell>30/0</cell><cell>Men</cell><cell></cell><cell>Men</cell><cell>30</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">27.3 ± 5.3</cell><cell>10.3 ± 8.3</cell><cell></cell><cell>Complete</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>remission</cell><cell>of</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>each</cell></row><row><cell></cell><cell>Colchicine</cell><cell>1-2 mg/day</cell><cell></cell><cell>0/28</cell><cell>Women</cell><cell></cell><cell>Women</cell><cell>28</cell><cell>mucocutaneous</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">26.7 ± 4.8</cell><cell>8 ± 8.8</cell><cell></cell><cell>lesion</cell><cell>and</cell></row><row><cell></cell><cell>Placebo</cell><cell></cell><cell></cell><cell>0/27</cell><cell>Women</cell><cell></cell><cell>Women</cell><cell>27</cell><cell>arthritis</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">27.2 ± 5.5</cell><cell>6.8 ± 6.8</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>136</cell></row><row><cell>Davatchi,</cell><cell>Colchicine</cell><cell>1mg/day</cell><cell></cell><cell>NA</cell><cell>32.1</cell><cell>±</cell><cell>6.4 ± 5.52</cell><cell></cell></row><row><cell>2009 [11]</cell><cell></cell><cell></cell><cell>16</cell><cell></cell><cell>8.29</cell><cell></cell><cell></cell><cell></cell><cell>IBDDAM score</cell></row><row><cell></cell><cell>Placebo</cell><cell></cell><cell></cell><cell>NA</cell><cell></cell><cell></cell><cell></cell><cell>146</cell></row><row><cell>Yazici,</cell><cell>Azathioprine</cell><cell>2.5 mg/Kg/day</cell><cell></cell><cell>34/0</cell><cell>Group 1</cell><cell></cell><cell>Group 1</cell><cell>34</cell></row><row><cell>1990 [12]</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">31.8 ± 4.3</cell><cell>2.7±2.6</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Group 2</cell><cell></cell><cell>Group 2</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>104</cell><cell></cell><cell cols="2">32.1 ± 5.3</cell><cell>8.6±6.3</cell><cell></cell><cell>Withdrawal</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>due to eye</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Group 1</cell><cell></cell><cell>Group 1</cell><cell></cell><cell>disease</cell></row><row><cell></cell><cell>Placebo</cell><cell></cell><cell></cell><cell>23/0</cell><cell cols="2">30.5 ± 5.2</cell><cell>5.2 ± 3.4</cell><cell>23</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Group 2</cell><cell></cell><cell>Group 2</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">31.5 ± 6.5</cell><cell>6.9 ± 6.8</cell><cell></cell></row><row><cell>Alpsoy, 2002 [13]</cell><cell>Systemic Interferon</cell><cell>6x10 6/ 3 times per</cell><cell></cell><cell>16/7</cell><cell>± 8.17 32.82</cell><cell></cell><cell>5.70 6.54 ±</cell><cell>23</cell></row><row><cell></cell><cell>alpha-2a</cell><cell>week</cell><cell>12</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Frequency and</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>duration</cell><cell>of</cell></row><row><cell></cell><cell>Placebo</cell><cell></cell><cell></cell><cell>11/10</cell><cell cols="2">± 7.85 31.89</cell><cell>5.83 6.33 ±</cell><cell>21</cell><cell>each lesion mucocutaneous and</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>articular</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>symptom</cell></row><row><cell>Hamuryudan, 1991 [22]</cell><cell>Topical alpha Interferon</cell><cell>1 x 10 5 U/g t.i.d.</cell><cell></cell><cell>NA</cell><cell>NA</cell><cell></cell><cell>NA</cell><cell>30</cell></row><row><cell></cell><cell></cell><cell></cell><cell>24</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Number of oral</cell></row><row><cell></cell><cell>Placebo</cell><cell></cell><cell></cell><cell>NA</cell><cell>NA</cell><cell></cell><cell>NA</cell><cell>31</cell><cell>ulcers</cell></row><row><cell>Melikoglu,</cell><cell>Etanercept</cell><cell>50mg/week</cell><cell>4</cell><cell>20/0</cell><cell cols="2">28.5 ± 5.3</cell><cell>2.8 ± 2.6</cell><cell>20</cell></row><row><cell>2005 [14]</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Suppression of</cell></row><row><cell></cell><cell>Placebo</cell><cell></cell><cell></cell><cell>20/0</cell><cell cols="2">30.8 ± 6.2</cell><cell>4.3 ± 3.2</cell><cell>20</cell><cell>the pathergy response and</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>monosodium</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>urate tests</cell></row></table><note><p><s>MU: million unit, NA: not available; BID: twice a day; TID.: three times a day</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_7"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Efficacy of interventions for oral ulcers</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell>Intervention</cell><cell>Comparator</cell><cell>Effect</cell><cell>Number of events /</cell></row><row><cell cols="2">Outcome</cell><cell>(n)</cell><cell>(n)</cell><cell></cell><cell>Mean values</cell><cell>Risk</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>of</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Bias</cell></row><row><cell cols="2">Improvem</cell><cell>Colchicine</cell><cell>Placebo</cell><cell>RR 0.75</cell><cell>14/14 vs 12/14</cell><cell>LOW</cell></row><row><cell cols="2">ent in ulcer</cell><cell>(n=14)</cell><cell>(n=14)</cell><cell>(0.48 to 1.17)</cell><cell></cell></row><row><cell cols="2">score at 3</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">months [9]</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">Number of</cell><cell>Colchicine</cell><cell>Placebo</cell><cell>Men</cell><cell>Men</cell><cell>LOW</cell></row><row><cell cols="2">oral ulcers</cell><cell>(n=30 men,</cell><cell>(n=30 men,</cell><cell>MD 0.80</cell><cell>25.7 ± 14 vs 24.9 ± 19.7</cell></row><row><cell cols="2">during 2</cell><cell>28 women)</cell><cell>27 women)</cell><cell>(-7.83 to 9.47)</cell><cell>Women</cell></row><row><cell cols="2">years [10]</cell><cell></cell><cell></cell><cell>Women</cell><cell>15.6 ± 12.3 vs 21.3 ± 13.6</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>MD -5.73</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>(-12.6 to 1.16)</cell><cell></cell></row><row><cell>IBDDAM</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>score</cell><cell>at</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">week 16</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>[</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p><s>The task force thanks EULAR for financial and logistic support.</s><s>The Parker Institute, Bispebjerg and Frederiksberg Hospital (R. Christensen) is supported by a core grant from the Oak Foundation (OCAY-13-309).</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0" />			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Behcet&apos;s syndrome</title>
		<author>
			<persName><forename type="first">G</forename><surname>Hatemi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yazici</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yazici</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rheum Dis Clin North Am</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="245" to="261" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center</title>
		<author>
			<persName><forename type="first">E</forename><surname>Kural-Seyahi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Fresko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Seyahi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Medicine</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="60" to="76" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">What affects the quality of life in patients with Behcet&apos;s disease?</title>
		<author>
			<persName><forename type="first">M</forename><surname>Melikoglu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Melikoglu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Reumatol Port</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="46" to="53" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">EULAR recommendations for the management of Behcet disease</title>
		<author>
			<persName><forename type="first">G</forename><surname>Hatemi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Silman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Bang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1656" to="1662" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation</title>
		<author>
			<persName><forename type="first">L</forename><surname>Shamseer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Moher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Clarke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMJ</title>
		<imprint>
			<biblScope unit="volume">349</biblScope>
			<biblScope unit="page">7647</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Updated method guidelines for cochrane musculoskeletal group systematic reviews and metaanalyses</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Ghogomu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Maxwell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Buchbinder</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The Journal of rheumatology</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="194" to="205" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">H</forename><surname>Guyatt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Thorlund</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Oxman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Epidemiol</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="173" to="183" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">H</forename><surname>Guyatt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Oxman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Santesso</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Epidemiol</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="158" to="172" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">A double blind study of colchicine in Behcet&apos;s disease</title>
		<author>
			<persName><forename type="first">E</forename><surname>Aktulga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Altac</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Muftuoglu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="399" to="402" />
			<date type="published" when="1980">1980</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">A double-blind trial of colchicine in Behcet&apos;s syndrome</title>
		<author>
			<persName><forename type="first">S</forename><surname>Yurdakul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tuzun</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="2686" to="2692" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Colchicine versus placebo in Behcet&apos;s disease: randomized, double-blind, controlled crossover trial</title>
		<author>
			<persName><forename type="first">F</forename><surname>Davatchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sadeghi</forename><surname>Abdollahi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Tehrani</forename><surname>Banihashemi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mod Rheumatol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="542" to="549" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">A controlled trial of azathioprine in Behcet&apos;s syndrome</title>
		<author>
			<persName><forename type="first">H</forename><surname>Yazici</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Pazarli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Barnes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">322</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="281" to="285" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study</title>
		<author>
			<persName><forename type="first">E</forename><surname>Alpsoy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Durusoy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Yilmaz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Dermatol</title>
		<imprint>
			<biblScope unit="volume">138</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="467" to="471" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Short-term trial of etanercept in Behcet&apos;s disease: a double blind, placebo controlled study</title>
		<author>
			<persName><forename type="first">M</forename><surname>Melikoglu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Fresko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mat</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="98" to="105" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial</title>
		<author>
			<persName><forename type="first">V</forename><surname>Hamuryudan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Saip</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="443" to="450" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Inefficacy of topical alpha interferon in the treatment of oral ulcers of Behcet&apos;s syndrome: a randomized, double blind trial</title>
		<author>
			<persName><forename type="first">V</forename><surname>Hamuryudan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yurdakul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Rosenkaimer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yazici</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="395" to="396" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Low-dose natural human interferon-alpha lozenges in the treatment of Behcet&apos;s syndrome</title>
		<author>
			<persName><forename type="first">H</forename><surname>Kilic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">E</forename><surname>Zeytin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Korkmaz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rheumatology (Oxford)</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1388" to="1391" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<monogr>
		<title level="m" type="main">Comparing the Effect of Phenytoin Syrup and Triamcinolone Acetonide Ointment on Aphthous Ulcers in Patients with Behcet&apos;s Syndrome</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Fani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ebrahimi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pourshahidi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Aflaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Shafiee</forename><surname>Sarvestani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
		<imprint>
			<date type="published" when="2012">2012</date>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="75" to="78" />
			<pubPlace>Iran Red Crescent Med J</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Topical cyclosporine-A for treatment of oral ulcers of Behcet&apos;s syndrome</title>
		<author>
			<persName><forename type="first">T</forename><surname>Ergun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Gurbuz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yurdakul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Hamuryudan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Bekiroglu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yazici</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Dermatol</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page">720</biblScope>
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades-Behcet&apos;s disease</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">D</forename><surname>Adler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Mansmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Zouboulis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dermatology</title>
		<imprint>
			<biblScope unit="volume">203</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="322" to="324" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Mycophenolate sodium in the treatment of mucocutaneous Behcet&apos;s diseases</title>
		<author>
			<persName><forename type="first">O</forename><surname>Kose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Simsek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pay</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Dermatol</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="895" to="896" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Effects of azithromycin on intracellular cytokine responses and mucocutaneous manifestations in Behcet&apos;s disease</title>
		<author>
			<persName><forename type="first">G</forename><surname>Mumcu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Inanc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">T</forename><surname>Ozdemir</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Dermatol</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1561" to="1566" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Treatment of mucocutaneous manifestations in Behcet&apos;s disease with anakinra: a pilot open-label study</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Grayson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yazici</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Merideth</surname></persName>
		</author>
		<idno>69. 30</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Res Ther</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">1</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Anakinra treatment in drug-resistant Behcet&apos;s disease: a case series</title>
		<author>
			<persName><forename type="first">L</forename><surname>Cantarini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Vitale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Scalini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1293" to="1301" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Efficacy and safety profile of anti-interleukin-1 treatment in Behcet&apos;s disease: a multicenter retrospective study</title>
		<author>
			<persName><forename type="first">G</forename><surname>Emmi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Talarico</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Lopalco</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1281" to="1286" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Lack of efficacy of tocilizumab in mucocutaneous Behcet&apos;s syndrome: report of two cases</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Diamantopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Hatemi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rheumatology (Oxford)</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1923" to="1924" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Paradoxical mucocutaneous flare in a case of Behcet&apos;s disease treated with tocilizumab</title>
		<author>
			<persName><forename type="first">L</forename><surname>Cantarini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Lopalco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Vitale</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1141" to="1143" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Pimecrolimus versus placebo in genital aphthous ulcers of Behcet&apos;s disease: a randomized double-blind controlled trial</title>
		<author>
			<persName><forename type="first">C</forename><surname>Chams-Davatchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Barikbin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Shahram</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="253" to="258" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Randomized trial of pimecrolimus cream plus colchicine tablets versus colchicine tablets in the treatment of genital ulcers in Behcet&apos;s disease</title>
		<author>
			<persName><forename type="first">O</forename><surname>Kose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dinc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Simsek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dermatology</title>
		<imprint>
			<biblScope unit="volume">218</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="140" to="145" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behcet&apos;s disease. A randomized clinical trial</title>
		<author>
			<persName><forename type="first">M</forename><surname>Calguneri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kiraz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Ertenli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Benekli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Karaarslan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Celik</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="2062" to="2065" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Inefficacy of azapropazone in the acute arthritis of Behcet&apos;s syndrome: a randomized, double blind, placebo controlled study</title>
		<author>
			<persName><forename type="first">F</forename><surname>Moral</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Hamuryudan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yurdakul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yazici</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clinical and experimental rheumatology</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="493" to="495" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Effects of interferon alpha treatment on the clinical course of refractory Behcet&apos;s disease: an open study</title>
		<author>
			<persName><forename type="first">M</forename><surname>Calguneri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Ozturk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Ertenli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kiraz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Apras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Ozbalkan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Rheum Dis</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="492" to="493" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behcet disease: results of an open 4-center trial</title>
		<author>
			<persName><forename type="first">I</forename><surname>Kotter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Vonthein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zierhut</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="311" to="319" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Systemic interferon alpha 2b treatment in Behcet&apos;s syndrome</title>
		<author>
			<persName><forename type="first">V</forename><surname>Hamuryudan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Moral</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yurdakul</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Rheumatol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1098" to="1100" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Interferon therapy for Behcet&apos;s disease</title>
		<author>
			<persName><forename type="first">E</forename><surname>Alpsoy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Yilmaz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Basaran</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Acad Dermatol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="617" to="619" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Anti-TNF-alpha therapy for sight threatening uveitis</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">W</forename><surname>Lindstedt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Baarsma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Kuijpers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Van Hagen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Ophthalmol</title>
		<imprint>
			<biblScope unit="volume">89</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="533" to="536" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Anti-TNF-alpha therapy in seven patients with Behcet&apos;s uveitis: advantages and controversial aspects</title>
		<author>
			<persName><forename type="first">S</forename><surname>Tognon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Graziani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Marcolongo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann N Y Acad Sci</title>
		<imprint>
			<biblScope unit="volume">1110</biblScope>
			<biblScope unit="page" from="474" to="484" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet&apos;s disease</title>
		<author>
			<persName><forename type="first">S</forename><surname>Iwata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Saito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yamaoka</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rheumatology (Oxford)</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1012" to="1013" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Efficacy of anti-TNF alpha in severe and/or refractory Behcet&apos;s disease: Multicenter study of 124 patients</title>
		<author>
			<persName><forename type="first">H</forename><surname>Vallet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Riviere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sanna</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Autoimmun</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="67" to="74" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Interferon alfa-associated depression in patients with Behcet&apos;s syndrome: a prospective controlled study</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Keskin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Seyahi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Poyraz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ugurlu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ozyazgan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yazici</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Rheumatol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page">S175</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>Suppl 84</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
